key: cord-0849614-0t15fpbq
authors: Foo, Suan-Sin; Cambou, Mary Catherine; Mok, Thalia; Fajardo, Viviana M.; Jung, Kyle L.; Fuller, Trevon; Chen, Weiqiang; Kerin, Tara; Mei, Jenny; Bhattacharya, Debika; Choi, Younho; Wu, Xin; Xia, Tian; Shin, Woo-Jin; Cranston, Jessica; Aldrovandi, Grace; Tobin, Nicole; Contreras, Deisy; Ibarrondo, Francisco J.; Yang, Otto; Yang, Shangxin; Garner, Omai; Cortado, Ruth; Bryson, Yvonne; Janzen, Carla; Ghosh, Shubhamoy; Devaskar, Sherin; Asilnejad, Brenda; Moreira, Maria Elisabeth; Vasconcelos, Zilton; Soni, Priya R.; Gibson, L. Caroline; Brasil, Patricia; Comhair, Suzy AA.; Arumugaswami, Vaithilingaraja; Erzurum, Serpil C.; Rao, Rashmi; Jung, Jae U.; Nielsen-Saines, Karin
title: The systemic inflammatory landscape of COVID19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in-utero SARS-CoV-2
date: 2021-10-27
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100453
sha: 46bb7895b89af4a241eb86c107aa3697a5b09b34
doc_id: 849614
cord_uid: 0t15fpbq

While pregnancy increases the risk for severe COVID19, the clinical and immunological implications of COVID19 on maternal-fetal health remain unknown. Here, we present the clinical and immunological landscapes of 93 COVID19 mothers and 45 of their SARS-CoV-2-exposed infants through comprehensive serum proteomics profiling for >1400 cytokines of their peripheral and cord blood specimens. Prenatal SARS-CoV-2 infection triggers NF-κB-dependent proinflammatory immune activation. Pregnant women with severe COVID19 show increased inflammation and unique IFNλ antiviral signaling, with elevated levels of IFNL1 and IFNLR1. Furthermore, SARS-CoV-2 infection re-shapes maternal immunity at delivery altering the expression of pregnancy complication-associated cytokines, inducing MMP7, MDK, ESM1, and reducing BGN and CD209. Finally, COVID19-exposed infants exhibit induction of T cell-associated cytokines (IL33, NFATC3 and CCL21), while some undergo IL-1β/IL-18/CASP1 axis-driven neonatal respiratory distress despite birth at term. Our findings demonstrate COVID19-induced immune rewiring in both mothers and neonates, warranting long-term clinical follow-up to mitigate potential health risks.

When we compared the serum immune profiles of healthy pregnant women between 256 delivery and second or third trimester of their pregnancies, we observed a large number of 257 significantly altered cytokines (P < 0.05; Figure 4D ). Among the 666 cytokines that were 258 affected (P < 0.05) at delivery compared to second trimester pregnancies,169 cytokines were 259 significantly induced (FC > 2) and six cytokines were repressed (FC < -2; Figure 4E ). On the 260 other hand, 623 cytokines were altered at delivery when compared to third trimester 261 pregnancies, with 188 cytokines significantly induced (FC > 2) and two cytokines repressed (FC reshaping of serum immune profiles.

To characterize how COVID19 diagnosis at different pregnancy stages affected immune 265 response at delivery, we analyzed serial serum specimens from patients diagnosed with 266 COVID19 during the second trimester (n = 9) or the third trimester of pregnancy (n = 18) and at 267 the time of their respective deliveries ( Figure 4D ). To identify the immune alterations at the time of delivery specifically associated with prenatal SARS-CoV-2 infection, we made comparisons 269 across the various pregnancy groups: (i) Healthy controlsdelivery (n = 14) versus second 270 trimester (n = 5); (ii) Healthy controlsdelivery (n = 14) versus third trimester (n = 6); (iii) 271 COVID19 follow-updelivery versus second trimester (n = 9); and (iv) COVID19 follow-up -272 delivery versus third trimester (n = 18; Figure 4E ). This analysis identified seven cytokines and 273 21 cytokines that were significantly altered (P < 0.05; -2 < FC >2) at delivery when SARS-CoV-2 274 infection occurred in the second and third trimesters of pregnancy, respectively ( Figure 4E ). 

preeclampsia and fetal growth restriction ( Figure 4J and Table 1B ). These data demonstrated 287 that SARS-CoV-2 infection at different stages of pregnancy may differentially dysregulate 288 maternal peripheral immunity, with potential implications for pregnancy-related complications.

Gestational exposure to SARS-CoV-2 alters infant immunity at birth 291 Inflammatory responses in pregnant women may potentially modulate infant immunity. 38

To examine the effects of in utero exposure of SARS-CoV-2 on neonatal immune responses, 293 peripheral blood (healthy, n = 7; COVID19-exposed, n = 45) and cord blood specimens (healthy, changes of serum cytokines in peripheral blood (nine cytokines) and cord blood (seven 297 cytokines) in comparison to infants from healthy mothers ( Figure 5B ). This was considerably 298 different from the maternal blood of women with COVID19 which showed drastic changes (171 299 cytokines) in serum cytokines when compared with healthy maternal blood. Induction of the IL-300 6R was commonly observed in both COVID19-positive maternal blood (mean FC = 3.24) and 301 COVID19-exposed infant blood (mean FC = 12.6; Figure 5C ), but not in cord blood ( Figure 5C ).

Sera cord blood from 32 COVID19-exposed infants was distinct from sera obtained in the first 303 day of life from these infants with no overlap ( Figure 5B ). There was also minimal overlap 304 between the cytokine profile of mothers at the time of acute infection during pregnancy or 305 delivery with that of infants at the time of birth ( Figure 5B and S3C).

While 90 cytokines were detectably altered (P < 0.05) in COVID19-exposed infants as 307 compared to healthy infants, eight cytokines were significantly induced (FC > 2) and two 

In order to further correlate maternal COVID19 disease severity with the neonatal 319 immune landscape, COVID19-exposed infants (n = 45) were grouped according to maternal 320 COVID19 disease severity: (i) asymptomatic (n = 11), (ii) mild/moderate (n = 28), and (iii) 321 severe/critical (n = 6). Seven infants from healthy mothers were included as controls. The 322 immune landscape of infants born to mothers with severe/critical COVID19 was distinct from 323 that of infants from mothers with asymptomatic or mild/moderate illness and infants from healthy 324 mothers ( Figure 6A ). Comparison analysis between the asymptomatic and symptomatic groups 325 of COVID19-exposed infants revealed a stronger immune activation in infants born to mothers 326 who had severe illness ( Figure 6B ). Upon comparison to infants from healthy mothers, 60 327 cytokines in infants born to asymptomatic COVID19 mothers, 272 cytokines in infants born to 328 mild/moderate COVID19 mothers, and 455 cytokines in infants born to severe/critical COVID19 that were significantly altered (P < 0.05) in infants born to asymptomatic COVID19 mothers, 331 only SIRPA was markedly altered and specific to the exposure of asymptomatic COVID19 332 mothers (mean FC = 9.86; Figure 6D ). Seven cytokines -IL-6R (mean FC = 13.01), NCLN 

In our infant cohort, 33.3% infants had respiratory distress (Table 1C ). Since premature 342 infants frequently have respiratory distress requiring oxygen supplementation, we sought to 343 delineate the specific immune alterations resulting from possible COVID19 exposure-associated 344 respiratory distress in term infants. We categorized infants as: (i) no (-) respiratory distress (RD)

pre-term birth (n = 3), (ii) (-) RDterm birth (n = 27), (iii) with (+) RDpre-term birth (n = 11), 346 and (iv) (+) RDterm birth (n = 4) ( Figure 6H ). Compared with healthy control infants (n = 7), 347 preterm COVID19-exposed infants with respiratory distress exhibited the most significant 348 immune alterations of 36 cytokines ( Figure S4C ). We identified five specific cytokines that were 349 affected in COVID19-exposed term birth infants with respiratory distress, including IDUA (mean 

reflective of our institution's status as a quaternary referral center for complex cases. Despite 371 this referral bias, 12.9% of women included in our series were asymptomatic, and 65.6% had 372 mild or moderate disease. Although our study is not a pregnancy registry and the analysis is not 373 powered to focus on clinical outcomes, our findings illustrate the degree to which disease 374 severity of pregnant women with COVID19 can manifest, including ARDS requiring ECMO and 375 maternal death. Of note, nearly half of our cohort is Latina, and the majority of participants with 376 severe/critical disease had public insurance, reflective of systemic inequities that manifested in 377 the national data as well. 5,10 It was notable that 60.0% of our participants with severe/critical 378 disease were diagnosed during the second trimester, which warrants further investigation. The 

Prenatal COVID19 exposure may alter neonatal T cell immunity and 446 neurodevelopment: The neonatal immunity is heavily skewed towards the innate immune arm 447 rather than the adaptive T cell immunity which is considered immature and immunodeviant. 56,57

In our COVID19-exposed infant cohort, we observed overt expressions of T cell-related 449 cytokines such as IL-33, NFATC3, and CCL21 in infant blood and IL-27 in the cord blood, 

The overwhelming Th2 responses in the COVID19-exposed infants is something that requires of Wnt/-catenin signaling pathway, 67 was also induced in these infants. These opposing effects inflammation, 68,69 was also highly expressed in infants born to mothers with severe/critical 476 COVID19. The negative impact of gestational inflammation and deregulated Wnt/-catenin 477 signaling pathway on neurodevelopment suggests that infants exposed to severe/critical 478 COVID19 may be at risk for neurodevelopmental complications, warranting long-term clinical 479 monitoring.

Respiratory distress of term COVID19-exposed infants is associated with NLRP3 481 inflammasome activation: In our study, 33.3% of the COVID19-exposed infants developed 482 respiratory distress. While some of these respiratory distress cases were likely due to preterm 483 births and Cesarean delivery, four infants were born at term to mothers with either 484 asymptomatic or symptomatic COVID19. Immunological evaluations of term COVID19-exposed 485 infants who developed respiratory distress identified high levels of IL-18, IL-1 and CASP1, 486 indicative of an activated NLRP3 inflammasome pathway. High levels of TREM2, known to 487 promote macrophage survival and viral-induced lung pathogenesis, 70 were detected in the in the airway. Therefore, these proteins are potential pathogenic factors implicated in respiratory 493 distress associated with prenatal COVID19-exposure in term infants. 

Despite the lack of robust evidence for vertical transmission, SARS-CoV-2 infection in 501 pregnancy appears to trigger prenatal immune activation that may lead to adverse maternal and 502 neonatal outcomes. Notably, prenatal COVID19-exposure led to sustained inflammation during 503 gestation and dysregulation of key signaling pathways that potentially could affect long-term 504 infant immune maturation and neurodevelopment. In summary, our findings highlight the 505 importance of long-term clinical monitoring of mother-infant dyads following COVID19+ 506 pregnancies. Follow-up of our cohort is ongoing with continued monitoring of these mother-507 infant pairs. 508 509

This study is an exploratory study and correlation should always be interepreted with caution in 511 an observational study, as confounding and reverse causality cannot be excluded. Next, UCLA 512 is a quaternary referral hospital, therefore our cohort was biased toward severe/critical cases.

However, the heterogeneity of our cohort was also a major strength, as we were able to explore 514 differences in proteomic profiles across disease severity classes as a result. Finally, our study 515 does not propose a conclusive, underlying biological mechanism to explain these findings.

Rather, this work generated provocative questions which will be explored in the future with 517 animal models, and warrant long-term clinical monitoring of mother-infant dyads.

J o u r n a l P r e -p r o o f 

(F and G) Cytokines highly upregulated and downregulated in asymptomatic COVID19 pregnant 572 women. Data are presented as mean  SEM, using One-way ANOVA Kruskal-Wallis with 573 uncorrected Dunn's test. *P < 0.05, **P < 0.01.

presented as mean  SEM, using One-way ANOVA Kruskal-Wallis with uncorrected Dunn's 578 test. *P < 0.05, ***P < 0.001, ****P < 0.0001. analyses were made between delivery blood specimens and pre-delivery 2 nd /3 rd trimester blood (E) Comparison analysis of cytokines significantly altered (P < 0.05; -2 < FC > 2) at delivery in 609 healthy or COVID19 pregnant women in contrast to cytokines observed in the 2 nd /3 rd trimester of 610 pregnancy in both groups.

(F and G) Cytokines of SARS-CoV-2-infected pregnant women significantly altered at delivery 612 compared to (F) 2 nd trimester or (G) 3 rd trimester infection cytokine profiles. 

(A) Schematic representation of COVID19-exposed infants in this study. Blood specimens were 622 collected from infants at Day 1 of life to healthy mothers (n = 7) or to SARS-CoV-2-infected 623 mothers (n = 45). Cord blood specimens were collected at delivery from healthy (n = 14) or 624 COVID19-exposed (n = 32) pregnancies.

(B) Comparison analysis of COVID19-induced serum cytokines of mothers (time of initial 626 diagnosis; n = 79), infant (n = 45) and/or cord blood (n = 32) specimens.

(C) IL-6R expression in mother-infant pairs. Data are presented as mean  SEM, using Mann-628 Whitney U test. *P < 0.05, **P < 0.01.

(D and E) Volcano plot illustrating the cytokines that are significantly altered (P < 0.05, -2 < FC 630 > 2) in whole blood (D) or cord blood (E) of COVID19-exposed infants compared to infants born 631 to healthy mothers.

(F and G) Cytokines exclusively affected in whole blood (F) or cord blood (G) of COVID19-633 exposed infants compared to that of infants born to healthy mothers. Data are presented as 634 mean  SEM, using Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 635 636 Figure 6 . Neonatal immune signatures of infants exposed to maternal severe COVID19 or 637 infants who had respiratory distress at birth 638 (A) Serum proteomic profiles of healthy control infants (n = 7) and COVID19-exposed infants 639 according to maternal disease presentation (asymptomatic, n = 11; mild/moderate, n = 28; and (C) Volcano plot illustrating the cytokines that are significantly altered (P < 0.05 and -2 < FC > 2) 645 in serum specimens of COVID19-exposed infants born to women who had severe/critical illness 646 in comparison to cytokines present in infants born to healthy mothers. (I) Serum cytokines specifically altered in (+)RD: Term (n = 4) COVID-19-exposed infants. Data presented as mean  SEM, using One-way ANOVA Kruskal-Wallis with uncorrected Dunn's 657 test. *P < 0.05, **P < 0.01, ***P < 0.001. 

 This paper does not report original code.

 Any additional information required to reanalyze the data reported in this work paper is 693 available from the Lead Contact upon request. the Olink Explore assay runs were then normalized using 10 repeated samples.

Heatmaps comparing cytokine expression for this study were generated in R (R Core 820 Team, 2020) using the pheatmap package (Kolde, 2019) and RColorBrewer (Neuwirth, 2014) .

Volcano plots in this study were generated in R (R Core Team, 2020) using the ggplot2 package using the following equation: 

Comparison between (iii) healthy delivery and COVID19+ delivery; (iv) healthy and COVID19-843 exposed infants; (v) healthy and various COVID19 severity-exposed infants or infants 844 presenting respiratory distress, were performed using Welch t-test. Comparison between 845 COVID19-initial diagnosis and COVID19-delivery was performed using paired t-test.

Comparison analyses (i) to (v) were performed using R. For all other analyses, Mann-Whitney U 847 test was used for comparison between two groups and one-way ANOVA Kruskal-Wallis with 848 uncorrected Dunn's test was used for comparison among three groups. According to G*Power 

Healthy (n = 14) COVID19+ (n = 49)

Healthy (n = 7) COVID19-exposed (n = 45)

Cord blood Healthy (n = 14) COVID19-exposed (n = 32)

High-throughput sera proteome multiplexing (1440 proteins) 

Textbook of pediatric infectious diseases

Medawar's Paradox and Immune 28

Proportion of asymptomatic coronavirus 1001 disease 2019: A systematic review and meta-analysis

The kallikrein-kinin system: current and future pharmacological targets

Inhibition of kallikrein-related peptidases by the serine protease 1008 inhibitor of Kazal-type 6

Potential role of high-mobility group box 1 protein in the pathogenesis of 1011 influenza H5N1 virus infection

Anti-high mobility group box-1 monoclonal 1014 antibody treatment provides protection against influenza A virus (H1N1)-induced 1015 pneumonia in mice

Targeting the 1017 interleukin-17 pathway to prevent acute respiratory distress syndrome associated with 1018 SARS-CoV-2 infection

Implications of SARS-Cov-2 1020 infection on eNOS and iNOS activity: consequences for the respiratory and vascular 1021 systems

Pregnant women with COVID-19 and risk of adverse birth 1024 outcomes and maternal-fetal vertical transmission: a population-based cohort study in 1025

Untuned antiviral 1028 immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu 1029 comparison

Placental growth factor reverses 1031 decreased vascular and uteroplacental MMP-2 and MMP-9

MMP-7 and collagen types I and IV in hypertensive pregnancy

Changes in endothelial cell specific molecule 1 plasma levels during 1036 preeclamptic pregnancies compared to healthy pregnancies

Neonatal T Cells: A Reinterpretation

The 59

Expansion of Regulatory T Cells In Vitro and In 72

Laboratory testing of 2019 novel coronavirus ( 2019-nCoV) in suspected 1102 human cases: interim guidance

Rapid Decay 1105 of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of 1109 Infected Patients

Viral load of SARS-1111

CoV-2 in clinical samples

Performance Characteristics of SARS-CoV-2 PCR Tests in A Single Health System: 1115 Analysis of over 10,000 Results from Three Different Assays